SPY317.59+3.21 1.02%
DIA260.82+3.58 1.39%
IXIC10,617.44+69.69 0.66%

Morgan Stanley Maintains Overweight on NextCure, Raises Price Target to $52

Morgan Stanley maintains NextCure (NASDAQ:NXTC) with a Overweight and raises the price target from $33 to $52.

Benzinga · -

Morgan Stanley maintains NextCure (NASDAQ:NXTC) with a Overweight and raises the price target from $33 to $52.